FDA approves Pfizer Ruxience for adult patients to treat a wide range of diseases
-
Last Update: 2020-06-09
-
Source: Internet
-
Author: User
Search more information of high quality chemicals, good prices and reliable suppliers, visit
www.echemi.com
recently, Pfizer announced that the U.SFood andDrug(http://Administration (
FDA(http://) has approved Ruxience (rituximab-pvvr, ritusxixipro, rituxixixim) for the treatment of adult patients: non-Hodgkin lymphoma (NHL), chronic lymphocytic leukemia (CLL), granuloma with polyheonitis (GPA), micromysis (MPA)Ruxience is the bio-
pharmaceutical(http://of Roche-branded drug Rituxan, the first bio-biosimilar approved by the FDAIn November 2018, Truxima (rituximab-abbs, rituxixixim), developed by Celltrion and Teva, received FDA approval, becoming the first litoxic monogeneric drug approved by the U.SmarketThis approval is based on a review of a comprehensive packet that demonstrates the similarity between Ruxience and referenceproduct(http://This includes the results of a clinical comparative study of REFLECTIONS B3281006, conducted in CD20-positive patients with low tumor burden lifsaroma (FL), assessed Ruxience's efficacy, safety and immunoogenics, pharmacokinetics, and pharmacodynamics, and found no clinical differences in safety and efficacy compared tocontrol(http://
This article is an English version of an article which is originally in the Chinese language on echemi.com and is provided for information purposes only.
This website makes no representation or warranty of any kind, either expressed or implied, as to the accuracy, completeness ownership or reliability of
the article or any translations thereof. If you have any concerns or complaints relating to the article, please send an email, providing a detailed
description of the concern or complaint, to
service@echemi.com. A staff member will contact you within 5 working days. Once verified, infringing content
will be removed immediately.
